{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:19:09Z","timestamp":1794917949487,"version":"4.9.1"},"reference-count":88,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>\u03b2-lactams are the cornerstone of empiric and targeted antibiotic therapy for critically ill patients. Recently, there have been calls to use \u03b2-lactam therapeutic drug monitoring (TDM) within 24\u201348 hours after the initiation of therapy in critically ill patients. In this article, we review the dynamic physiology of critically ill patients, \u03b2-lactam dose response in critically ill patients, the impact of pathogen minimum inhibitory concentration (MIC) on \u03b2-lactam TDM, and pharmacokinetics in critically ill patients. Additionally, we highlight available clinical data to better inform \u03b2-lactam TDM for critically ill patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DATA SOURCES:<\/jats:title>\n            <jats:p>We retrospectively analyzed patients admitted for sepsis or septic shock at a single academic medical center who were treated with \u03b2-lactam antibiotics.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>STUDY SELECTION:<\/jats:title>\n            <jats:p>Indexed studies in PubMed in English language were selected for review on topics relative to critical care physiology, \u03b2-lactams, pharmacokinetics\/pharmacodynamics, TDM, and antibiotic susceptibility.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DATA EXTRACTION:<\/jats:title>\n            <jats:p>We reviewed potentially related studies on \u03b2-lactams and TDM and summarized their design, patients, and results. This is a synthetic, nonsystematic, review.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DATA SYNTHESIS:<\/jats:title>\n            <jats:p>In the retrospective analysis of patients treated with \u03b2-lactam antibiotics, approximately one-third of patients received less than 48 hours of \u03b2-lactam therapy. Of those who continued beyond 48 hours, only 13.7% had patient-specific factors (augmented renal clearance, fluid overload, morbid obesity, and\/or surgical drain), suggesting a potential benefit of \u03b2-lactam TDM.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>These data indicate that a strategy of comprehensive \u03b2-lactam TDM for critically ill patients is unwarranted as it has not been shown yet to improve patient-oriented outcomes. This review demonstrates that \u03b2-lactam TDM in the ICU, while laudable, layers ambiguous \u03b2-lactam exposure thresholds upon uncertain\/unknown MIC data within a dynamic, unpredictable patient population for whom TDM results will not be available fast enough to significantly affect care. Judicious, targeted TDM for those with risk factors for \u03b2-lactam over- or underexposure is a better approach but requires further study. Clinically, choosing the correct antibiotic and dosing \u03b2-lactams aggressively, which have a wide therapeutic index, to overcome critical illness factors appears to give critically ill patients the best likelihood of survival.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cce.0000000000000726","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T17:07:54Z","timestamp":1657040874000},"page":"e0726","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":26,"title":["\u03b2-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: Weighing the Challenges and Opportunities to Assess Clinical Value"],"prefix":"10.1097","volume":"4","author":[{"given":"Thomas J.","family":"Dilworth","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services, Advocate Aurora Health, Milwaukee, WI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas T.","family":"Schulz","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, UW Health, Madison, WI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott T.","family":"Micek","sequence":"additional","affiliation":[{"name":"Center for Health Outcomes Research and Education, University of Health Sciences and Pharmacy, St. Louis, MO."},{"name":"Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marin H.","family":"Kollef","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren E.","family":"Rose","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Wisconsin-Madison, Madison, WI."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,7,5]]},"reference":[{"key":"R1-20240807","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1001\/jama.2020.2717","article-title":"Prevalence and outcomes of infection among patients in intensive care units in 2017.","volume":"323","author":"Vincent","year":"2020","journal-title":"JAMA"},{"key":"R2-20240807","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: A position paper.","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"R3-20240807","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men.","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"R4-20240807","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1128\/AAC.00867-13","article-title":"Impact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa.","volume":"57","author":"Felton","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R5-20240807","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s40262-020-00919-6","article-title":"Prolonged versus intermittent infusion of \u03b2-lactam antibiotics: A systematic review and meta-regression of bacterial killing in preclinical infection models.","volume":"59","author":"Dhaese","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"R6-20240807","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1164\/rccm.201601-0024OC","article-title":"Continuous versus intermittent \u03b2-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials.","volume":"194","author":"Roberts","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"R7-20240807","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/cid\/cis856","article-title":"Continuous infusion of beta-lactam antibiotics in severe sepsis: A multicenter double-blind, randomized controlled trial.","volume":"56","author":"Dulhunty","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R8-20240807","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1128\/AAC.01190-09","article-title":"Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.","volume":"54","author":"Bulik","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R9-20240807","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.xphs.2016.02.008","article-title":"Comparison of short versus prolonged infusion of standard dose of meropenem against carbapenemase-producing Klebsiella pneumoniae isolates in different patient groups: A pharmacokinetic-pharmacodynamic approach.","volume":"105","author":"Vourli","year":"2016","journal-title":"J Pharm Sci"},{"key":"R10-20240807","first-page":"63","article-title":"Killing and regrowth of bacteria in vitro: A review.","volume":"74","author":"Craig","year":"1990","journal-title":"Scand J Infect Dis Suppl"},{"key":"R11-20240807","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1084\/jem.88.1.99","article-title":"The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms.","volume":"88","author":"Eagle","year":"1948","journal-title":"J Exp Med"},{"key":"R12-20240807","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1128\/AAC.34.1.94","article-title":"Paradoxical activity of beta-lactam antibiotics against Proteus vulgaris in experimental infection in mice.","volume":"34","author":"Ikeda","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"R13-20240807","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.tim.2018.10.007","article-title":"The Eagle effect and antibiotic-induced persistence: Two sides of the same coin?","volume":"27","author":"Prasetyoputri","year":"2019","journal-title":"Trends Microbiol"},{"key":"R14-20240807","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/jac\/dks468","article-title":"Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia.","volume":"68","author":"Muller","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"R15-20240807","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1345\/aph.1E271","article-title":"Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia.","volume":"39","author":"Ariano","year":"2005","journal-title":"Ann Pharmacother"},{"key":"R16-20240807","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1128\/AAC.02611-13","article-title":"Exposure to ceftobiprole is associated with microbiological eradication and clinical cure in patients with nosocomial pneumonia.","volume":"58","author":"Muller","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R17-20240807","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1128\/AAC.00294-06","article-title":"Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections.","volume":"51","author":"Li","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R18-20240807","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jac\/dkf130","article-title":"Pharmacodynamics of cefepime in patients with Gram-negative infections.","volume":"50","author":"Tam","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"R19-20240807","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1093\/jac\/dky279","article-title":"Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17).","volume":"73","author":"Sader","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R20-20240807","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1378\/chest.116.1.115","article-title":"A randomized, crossover design study of the pharmacology of extended-spectrum fluoroquinolones for pneumococcal infections.","volume":"116","author":"Amsden","year":"1999","journal-title":"Chest"},{"key":"R21-20240807","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1128\/AAC.04965-14","article-title":"Examining the use of ceftaroline in the treatment of Streptococcus pneumoniae meningitis with reference to human cathelicidin LL-37.","volume":"59","author":"Sakoulas","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R22-20240807","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/CMR.00007-10","article-title":"Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections.","volume":"23","author":"Nau","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"R23-20240807","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1086\/514622","article-title":"The pharmacodynamics of beta-lactams.","volume":"27","author":"Turnidge","year":"1998","journal-title":"Clin Infect Dis"},{"key":"R24-20240807","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/cid\/ciz460","article-title":"The emperor\u2019s new clothes: Prospective observational evaluation of the association between initial vancomycin exposure and failure rates among adult hospitalized Patients with Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE).","volume":"70","author":"Lodise","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R25-20240807","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","article-title":"Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.","volume":"43","author":"Moise-Broder","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R26-20240807","doi-asserted-by":"crossref","first-page":"O1098","DOI":"10.1111\/1469-0691.12695","article-title":"Impact of source of infection and vancomycin AUC0-24\/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia.","volume":"20","author":"Ghosh","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"R27-20240807","doi-asserted-by":"crossref","first-page":"e0146224","DOI":"10.1371\/journal.pone.0146224","article-title":"Association between the AUC0-24\/MIC ratio of vancomycin and its clinical effectiveness: A systematic review and meta-analysis.","volume":"11","author":"Men","year":"2016","journal-title":"PLoS One"},{"key":"R28-20240807","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41564-018-0342-0","article-title":"The high prevalence of antibiotic heteroresistance in pathogenic bacteria is mainly caused by gene amplification.","volume":"4","author":"Nicoloff","year":"2019","journal-title":"Nat Microbiol"},{"key":"R29-20240807","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.molcel.2019.09.028","article-title":"Bacterial heterogeneity and antibiotic survival: understanding and combatting persistence and heteroresistance.","volume":"76","author":"Dewachter","year":"2019","journal-title":"Mol Cell"},{"key":"R30-20240807","doi-asserted-by":"crossref","first-page":"105941","DOI":"10.1016\/j.ijantimicag.2020.105941","article-title":"Combination of polymyxin B and minocycline against multidrug-resistant Klebsiella pneumoniae: Interaction quantified by pharmacokinetic\/pharmacodynamic modelling from in vitro data.","volume":"55","author":"Zhao","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"R31-20240807","doi-asserted-by":"crossref","first-page":"1416.e5","DOI":"10.1016\/j.cmi.2020.06.032","article-title":"Expression of CTX-M-15 limits the efficacy of ceftolozane\/tazobactam against Escherichia coli in a high-inoculum murine peritonitis model.","volume":"26","author":"Canovas","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"R32-20240807","doi-asserted-by":"crossref","first-page":"e00703","DOI":"10.1128\/AAC.00703-20","article-title":"Cefazolin inoculum effect and methicillin-susceptible Staphylococcus aureus osteoarticular infections in children.","volume":"64","author":"McNeil","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R33-20240807","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciz089","article-title":"The Infectious Diseases Society of America\u2019s 10 \u00d7 \u201820 initiative (10 new systemic antibacterial agents US Food And Drug Administration approved by 2020): Is 20 \u00d7 \u201820 a possibility?","volume":"69","author":"Talbot","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R34-20240807","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1128\/JCM.44.3.1101-1104.2006","article-title":"Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents.","volume":"44","author":"Sader","year":"2006","journal-title":"J Clin Microbiol"},{"key":"R35-20240807","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.2147\/IDR.S166790","article-title":"Comparison of five commonly used automated susceptibility testing methods for accuracy in the China Antimicrobial Resistance Surveillance System (CARSS) hospitals.","volume":"11","author":"Zhou","year":"2018","journal-title":"Infect Drug Resist"},{"key":"R36-20240807","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1093\/jac\/dky232","article-title":"Variation of MIC measurements: The contribution of strain and laboratory variability to measurement precision.","volume":"73","author":"Mouton","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R37-20240807","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.ebiom.2015.08.012","article-title":"Host-dependent induction of transient antibiotic resistance: A prelude to treatment failure.","volume":"2","author":"Kubicek-Sutherland","year":"2015","journal-title":"EBioMedicine"},{"key":"R38-20240807","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ebiom.2017.05.026","article-title":"Correcting a fundamental flaw in the paradigm for antimicrobial susceptibility testing.","volume":"20","author":"Ersoy","year":"2017","journal-title":"EBioMedicine"},{"key":"R39-20240807","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1749-6632.2012.06796.x","article-title":"Metallo-\u03b2-lactamase structure and function.","volume":"1277","author":"Palzkill","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"R40-20240807","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/jac\/dkaa467","article-title":"The paradoxical in vivo activity of \u03b2-lactams against metallo-\u03b2-lactamase-producing Enterobacterales is not restricted to carbapenems.","volume":"76","author":"Abdelraouf","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"R41-20240807","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/jpids\/piz094","article-title":"Serum-associated antibiotic tolerance in pediatric clinical isolates of pseudomonas aeruginosa.","volume":"9","author":"Morrison","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R42-20240807","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1378\/chest.118.1.146","article-title":"The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting.","volume":"118","author":"Ibrahim","year":"2000","journal-title":"Chest"},{"key":"R43-20240807","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1378\/chest.115.2.462","article-title":"Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients.","volume":"115","author":"Kollef","year":"1999","journal-title":"Chest"},{"key":"R44-20240807","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/jhm.713","article-title":"Hospitalizations with healthcare-associated complicated skin and skin structure infections: Impact of inappropriate empiric therapy on outcomes.","volume":"5","author":"Zilberberg","year":"2010","journal-title":"J Hosp Med"},{"key":"R45-20240807","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jinf.2012.10.028","article-title":"Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: The study, the patient, the bug or the drug?","volume":"66","author":"Vardakas","year":"2013","journal-title":"J Infect"},{"key":"R46-20240807","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1097\/CCM.0000000000000516","article-title":"Using the number needed to treat to assess appropriate antimicrobial therapy as a determinant of outcome in severe sepsis and septic shock.","volume":"42","author":"Vazquez-Guillamet","year":"2014","journal-title":"Crit Care Med"},{"key":"R47-20240807","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1378\/chest.08-0842","article-title":"Antimicrobial therapy escalation and hospital mortality among patients with health-care-associated pneumonia: A single-center experience.","volume":"134","author":"Zilberberg","year":"2008","journal-title":"Chest"},{"key":"R48-20240807","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10928-017-9518-0","article-title":"PK-PD Compass: Bringing infectious diseases pharmacometrics to the patient\u2019s bedside.","volume":"44","author":"Bulik","year":"2017","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"R49-20240807","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/jcph.1977","article-title":"Time above all else: Pharmacodynamic analysis of \u03b2-lactams in critically ill patients.","volume":"62","author":"Landmesser","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"R50-20240807","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: Are current \u03b2-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R51-20240807","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s10096-012-1803-7","article-title":"A survey of beta-lactam antibiotics and vancomycin dosing strategies in intensive care units and general wards in Belgian hospitals.","volume":"32","author":"Buyle","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R52-20240807","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jcrc.2020.08.027","article-title":"The ONTAI study - a survey on antimicrobial dosing and the practice of therapeutic drug monitoring in German intensive care units.","volume":"60","author":"Liebchen","year":"2020","journal-title":"J Crit Care"},{"key":"R53-20240807","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/cid\/ciy790","article-title":"Renal dosing of antibiotics: Are we jumping the gun?","volume":"68","author":"Crass","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R54-20240807","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.","volume":"34","author":"Kumar","year":"2006","journal-title":"Crit Care Med"},{"key":"R56-20240807","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1093\/jac\/dky314","article-title":"Therapeutic drug monitoring of \u03b2-lactam antibiotics in the critically ill: Direct measurement of unbound drug concentrations to achieve appropriate drug exposures.","volume":"73","author":"Wong","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R57-20240807","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.clinthera.2017.06.008","article-title":"Clinical outcome and antimicrobial therapeutic drug monitoring for the treatment of infections in acute burn patients.","volume":"39","author":"Machado","year":"2017","journal-title":"Clin Ther"},{"key":"R58-20240807","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.burns.2015.01.001","article-title":"Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.","volume":"41","author":"Fournier","year":"2015","journal-title":"Burns"},{"key":"R59-20240807","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/phar.2505","article-title":"A guide to therapeutic drug monitoring of \u03b2-lactam antibiotics.","volume":"41","author":"Fratoni","year":"2021","journal-title":"Pharmacotherapy"},{"key":"R60-20240807","doi-asserted-by":"crossref","first-page":"e01818","DOI":"10.1128\/AAC.01818-17","article-title":"Impact of real-time therapeutic drug monitoring on the prescription of antibiotics in burn patients requiring admission to the intensive care unit.","volume":"62","author":"Fournier","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R61-20240807","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s00134-013-3187-2","article-title":"Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: A randomised controlled trial.","volume":"40","author":"De Waele","year":"2014","journal-title":"Intensive Care Med"},{"key":"R62-20240807","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1093\/jac\/dkaa359","article-title":"Early therapeutic monitoring of \u03b2-lactams and associated therapy outcomes in critically ill patients.","volume":"75","author":"Al-Shaer","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"R63-20240807","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ijantimicag.2017.04.023","article-title":"Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: A \u2018Goldilocks\u2019 window.","volume":"50","author":"Miglis","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"R64-20240807","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/00003246-199811000-00016","article-title":"Use of the SOFA score to assess the incidence of organ dysfunction\/failure in intensive care units: Results of a multicenter, prospective study. Working group on \u201csepsis-related problems\u201d of the European Society of Intensive Care Medicine.","volume":"26","author":"Vincent","year":"1998","journal-title":"Crit Care Med"},{"key":"R65-20240807","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12879-020-4781-x","article-title":"The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: The DOLPHIN trial protocol of a multi-centre randomised controlled trial.","volume":"20","author":"Abdulla","year":"2020","journal-title":"BMC Infect Dis"},{"key":"R67-20240807","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1136\/ejhpharm-2018-001713","article-title":"Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: A prospective cohort study in critically ill patients.","volume":"27","author":"Schoenenberger-Arnaiz","year":"2020","journal-title":"Eur J Hosp Pharm"},{"key":"R68-20240807","doi-asserted-by":"crossref","first-page":"e02019","DOI":"10.1128\/AAC.02019-20","article-title":"Model-optimized fluconazole dose selection for critically ill patients improves early pharmacodynamic target attainment without the need for therapeutic drug monitoring.","volume":"65","author":"Sandaradura","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"R69-20240807","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ijantimicag.2010.06.008","article-title":"Therapeutic drug monitoring of beta-lactams in critically ill patients: Proof of concept.","volume":"36","author":"Roberts","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"R70-20240807","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s40262-018-0636-7","article-title":"Augmented renal clearance in critically ill patients: A systematic review.","volume":"57","author":"Bilbao-Meseguer","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"R71-20240807","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1007\/s00134-014-3403-8","article-title":"Risk factors for target non-attainment during empirical treatment with \u03b2-lactam antibiotics in critically ill patients.","volume":"40","author":"De Waele","year":"2014","journal-title":"Intensive Care Med"},{"key":"R72-20240807","doi-asserted-by":"crossref","first-page":"R84","DOI":"10.1186\/cc12705","article-title":"Meropenem and piperacillin\/tazobactam prescribing in critically ill patients: Does augmented renal clearance affect pharmacokinetic\/pharmacodynamic target attainment when extended infusions are used?","volume":"17","author":"Carlier","year":"2013","journal-title":"Crit Care"},{"key":"R73-20240807","doi-asserted-by":"crossref","first-page":"e0180247","DOI":"10.1371\/journal.pone.0180247","article-title":"Augmented renal clearance is not a risk factor for mortality in Enterobacteriaceae bloodstream infections treated with appropriate empiric antimicrobials.","volume":"12","author":"Burnham","year":"2017","journal-title":"PLoS One"},{"key":"R74-20240807","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijantimicag.2016.12.022","article-title":"Association between augmented renal clearance and clinical outcomes in patients receiving \u03b2-lactam antibiotic therapy by continuous or intermittent infusion: A nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial.","volume":"49","author":"Udy","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"R75-20240807","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ijantimicag.2014.12.017","article-title":"Augmented renal clearance, low \u03b2-lactam concentrations and clinical outcomes in the critically ill: An observational prospective cohort study.","volume":"45","author":"Huttner","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"R76-20240807","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jcrc.2013.03.003","article-title":"Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy.","volume":"28","author":"Claus","year":"2013","journal-title":"J Crit Care"},{"key":"R77-20240807","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s13546-015-1060-8","article-title":"Optimization of antibiotic therapy in the obese, critically ill patient.","volume":"24","author":"Hites","year":"2015","journal-title":"R\u00e9animation"},{"key":"R78-20240807","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00134-021-06609-6","article-title":"Effect of therapeutic drug monitoring-based dose optimization of piperacillin\/tazobactam on sepsis-related organ dysfunction in patients with sepsis: A randomized controlled trial.","volume":"48","author":"Hagel","year":"2022","journal-title":"Intensive Care Med"},{"key":"R79-20240807","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1097\/CCM.0b013e318241e553","article-title":"Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: A multicentre pharmacokinetic study.","volume":"40","author":"Roberts","year":"2012","journal-title":"Crit Care Med"},{"key":"R80-20240807","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/jcpt.12636","article-title":"Pharmacokinetic changes of antibiotic, antiviral, antituberculosis and antifungal agents during extracorporeal membrane oxygenation in critically ill adult patients.","volume":"42","author":"Hahn","year":"2017","journal-title":"J Clin Pharm Ther"},{"key":"R81-20240807","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s13054-021-03680-9","article-title":"Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis.","volume":"25","author":"Pa\u0159\u00edzkov\u00e1","year":"2021","journal-title":"Crit Care"},{"key":"R82-20240807","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/ciaa303","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.","volume":"71","author":"Rybak","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R83-20240807","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0924-8579(02)00030-4","article-title":"Extended interval aminoglycoside dosing: From concept to clinic.","volume":"19","author":"Maglio","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"R84-20240807","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: Guidelines from the British Society for Medical Mycology.","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"R85-20240807","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s10096-005-0021-y","article-title":"Neurotoxicity induced by beta-lactam antibiotics: From bench to bedside.","volume":"24","author":"Chow","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R86-20240807","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/cid\/ciz1189","article-title":"Piperacillin-tazobactam added to vancomycin increases risk for acute kidney injury: Fact or fiction?","volume":"71","author":"Avedissian","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R87-20240807","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmi.2019.06.028","article-title":"Cefepime neurotoxicity: Thresholds and risk factors. A retrospective cohort study.","volume":"26","author":"Boschung-Pasquier","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"R88-20240807","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cmi.2017.01.005","article-title":"Cefepime plasma concentrations and clinical toxicity: A retrospective cohort study.","volume":"23","author":"Huwyler","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"R89-20240807","first-page":"27","article-title":"Continuous infusion of cefepime and neurotoxicity: A retrospective cohort study.","author":"Vercheval","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"R90-20240807","doi-asserted-by":"crossref","first-page":"e0446","DOI":"10.1097\/CCE.0000000000000446","article-title":"Setting the beta-lactam therapeutic range for critically ill patients: Is there a floor or even a ceiling?","volume":"3","author":"Barreto","year":"2021","journal-title":"Crit Care Explor"}],"container-title":["Critical Care Explorations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000726","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T14:17:28Z","timestamp":1723040248000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":88,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/cce.0000000000000726","relation":{},"ISSN":["2639-8028"],"issn-type":[{"value":"2639-8028","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}